Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00251433
Status:
TERMINATED
Last Update Posted:
2023-03-31
First Post:
2005-11-08
Brief Title:
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-09-26
Start Date Type:
ACTUAL
Primary Completion Date:
2010-06-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-06-22
Completion Date Type:
ACTUAL
First Submit Date:
2005-11-08
First Submit QC Date:
November 9 2005
Study First Post Date:
2005-11-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-29
Last Update Post Date:
2023-03-31
Last Update Post Date Type:
ACTUAL